Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term use of ticagrelor in patients with prior myocardial infarction

MP. Bonaca, DL. Bhatt, M. Cohen, PG. Steg, RF. Storey, EC. Jensen, G. Magnani, S. Bansilal, MP. Fish, K. Im, O. Bengtsson, T. Oude Ophuis, A. Budaj, P. Theroux, M. Ruda, C. Hamm, S. Goto, J. Spinar, JC. Nicolau, RG. Kiss, SA. Murphy, SD. Wiviott,...

. 2015 ; 372 (19) : 1791-800.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15022788
E-zdroje Online Plný text

NLK ProQuest Central od 1980-01-03 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest) od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci

Odkazy

PubMed 25773268
DOI 10.1056/nejmoa1500857
Knihovny.cz E-zdroje

BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P=0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P<0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022788
003      
CZ-PrNML
005      
20150724095240.0
007      
ta
008      
150709s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1056/NEJMoa1500857 $2 doi
035    __
$a (PubMed)25773268
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bonaca, Marc P $u From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (M.P.B., D.L.B., G.M., M.P.F., K.I., S.A.M., S.D.W., E.B., M.S.S.); the Cardiovascular Division, Department of Medicine, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire Fibrosis, Inflammation, Remodeling, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, INSERM Unité 1148, and Université Paris-Diderot, Sorbonne Paris Cité - all in Paris (P.G.S.); National Heart and Lung Institute, Royal Brompton Hospital, Imperial College, London (P.G.S.), and Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom (R.F.S.); AstraZeneca, Mölndal, Sweden (E.C.J., O.B., P.H.); Icahn School of Medicine at Mount Sinai, New York (S.B.); Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands (T.O.O.); Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland (A.B.); Montreal Heart Institute, Université de Montréal, Montreal (P.T.); Cardiology Research Center, Moscow (M.R.); Kerckhoff Heart Center, Bad Nauheim, and University of Giessen, Giessen - both in Germany (C.H.); Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Japan (S.G.); University Hospital, Jihlavska, Brno, Czech Republic (J.S.); Heart Institute (InCor)-University of São Paulo Medical School, São Paulo (J.C.N.); and the Department of Cardiology, Military Hospital, Budapest, Hungary (R.G.K.).
245    10
$a Long-term use of ticagrelor in patients with prior myocardial infarction / $c MP. Bonaca, DL. Bhatt, M. Cohen, PG. Steg, RF. Storey, EC. Jensen, G. Magnani, S. Bansilal, MP. Fish, K. Im, O. Bengtsson, T. Oude Ophuis, A. Budaj, P. Theroux, M. Ruda, C. Hamm, S. Goto, J. Spinar, JC. Nicolau, RG. Kiss, SA. Murphy, SD. Wiviott, P. Held, E. Braunwald, MS. Sabatine, . ,
520    9_
$a BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P=0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P<0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).
650    _2
$a adenosin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D000241
650    _2
$a senioři $7 D000368
650    _2
$a Aspirin $x aplikace a dávkování $7 D001241
650    _2
$a kardiovaskulární nemoci $x mortalita $x prevence a kontrola $7 D002318
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a intrakraniální krvácení $x chemicky indukované $7 D020300
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu $x farmakoterapie $7 D009203
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $7 D010975
650    _2
$a antagonisté purinergních receptorů P2Y $x aplikace a dávkování $x škodlivé účinky $7 D058921
650    _2
$a riziko $7 D012306
650    _2
$a sekundární prevence $7 D055502
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bhatt, Deepak L
700    1_
$a Cohen, Marc
700    1_
$a Steg, Philippe Gabriel
700    1_
$a Storey, Robert F
700    1_
$a Jensen, Eva C
700    1_
$a Magnani, Giulia
700    1_
$a Bansilal, Sameer
700    1_
$a Fish, M Polly
700    1_
$a Im, Kyungah
700    1_
$a Bengtsson, Olof
700    1_
$a Oude Ophuis, Ton
700    1_
$a Budaj, Andrzej
700    1_
$a Theroux, Pierre
700    1_
$a Ruda, Mikhail
700    1_
$a Hamm, Christian
700    1_
$a Goto, Shinya
700    1_
$a Spinar, Jindrich
700    1_
$a Nicolau, José Carlos
700    1_
$a Kiss, Robert G
700    1_
$a Murphy, Sabina A
700    1_
$a Wiviott, Stephen D
700    1_
$a Held, Peter
700    1_
$a Braunwald, Eugene
700    1_
$a Sabatine, Marc S
700    1_
$a ,
773    0_
$w MED00003517 $t The New England journal of medicine $x 1533-4406 $g Roč. 372, č. 19 (2015), s. 1791-800
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25773268 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150724095319 $b ABA008
999    __
$a ok $b bmc $g 1083127 $s 905781
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 372 $c 19 $d 1791-800 $i 1533-4406 $m The New England journal of medicine $n N Engl J Med $x MED00003517
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Možnosti archivace